26 April 2024
PBS listing of Saphnelo
At the March 2024 meeting, the PBAC has recommended the PBS listing of Saphnelo for patients with severe SLE with high disease activity despite standard of care.
AstraZeneca is working with the Department of Health to finalise the next steps to enable a timely PBS listing.
The Saphnelo outcome is copied below, the full set out outcomes can be found here: https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-march-2024
